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Review Article 
Ebola Virus Disease and its Complications 
ABSTRACT 
Now a day in African countries Ebola virus has been responsible for several deaths. In 
addition to being a global health concern, the virus also is considered a potential biological 
threat agent.  Ebola viruses are incompletely understood pathogens that cause severe, often 
fatal, illnesses in humans and non-human primates. Ebola virus disease affects most of the 
human being and finally mortality rate is increases in that county. Most of the countries are 
on alert for the ebola virus because maximum peoples who worked on the affected area of 
Africa without proper test in airport or other places he doesn’t enter in to the resident country. 
In this review we discuss ebola virus disease and how it affects the peoples worldwide.  
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1.INTRODUCTION 
Ebola is a rare but deadly virus that causes bleeding inside and outside the body. As the virus 
spreads through the body, it damages the immune system and body organs. Ultimately, it 
causes levels of blood-clotting cells to drop, finally leads to severe uncontrollable bleeding. 
The disease, also known as Ebola hemorrhagic fever or Ebola virus, kills up to 90% of people 
who are infected.  So far serious, Ebola cases have only shown up in Central and West 
Africa. Ebola can spread from country to country when people travel.  Ebola can feel like the 
flu or other illnesses. Symptoms show up 2 to 21 days after infection [1-4]. Cases and deaths 
from EVD in Guinea, Liberia, Nigeria, and Sierra Leone as of 31 July 2014 mentioned in 
table1. The spread of Ebola Virus Disease (EVD) between and within the three neighbouring 
countries accounting for the majority of the cases noted so far Guinea, Liberia, and Sierra 
Leone is due to high cross- border movement and the introduction of EVD in additional 
neighbouring countries in the sub region might not be excluded due to the existence of 
similarly porous borders [5].  
Table 1 EVD Cases and deaths in Guinea, Liberia, Nigeria, and Sierra Leone as of 31 
July 2014 
Country Cases Deaths Case Fatality 
Rate (%) 
Health care workers 
affected (Cases/Deaths) 
Guinea 472 346 73 33/20 
Liberia 360 181 50 47/28 
Nigeria 1 1 100 0 
Sierra Leone 574 215 37 44/33 
Total 1407 743 53 124/71 
2. STRUCTURE OF EBOLA VIRUS 
EBOV (Ebola Virus) carries a negative-sense RNA genome in virions that are 
cylindrical/tubular, and contain viral envelope, matrix, and nucleocapsid components. The 
overall cylinders are generally approx. 80 nm in diameter, and having a virally encoded 
glycoprotein (GP) projecting as 7-10 nm long spikes from its lipid bilayer surface (figure 1) 
[6]. 
The Ebola has characteristic "threadlike" structure, however, a more general morphologic 




The species is avirological taxon species included the genus in Ebolavirus family 
Filoviridae (members known as Filovirus) [8], order Mononegavirales [9]. The Zaire 
ebolavirus species is also the type species (reference or example species) for ebolavirus. Its 
natural reservoir is bats, particularly fruit bats.  
 
 
Figure 1 Structure of Ebola virus (Transmission electron micrograph) 
The EBOV genome is approximately 19,000 base pairs long. It encodes 7 structural 
proteins: nucleoprotein (NP), polymerasecofactor (VP35), (VP40), GP, transcription 
activator (VP30), VP24, and RNA polymerase (L) (figure 2) [10]. It is difficult to study due 
to the virulent nature of the virus. 
 
Figure 2 Virion structure of Ebola virus 
4. SPREAD 
Ebola spreads to people by contact with the skin or body fluids of an infected animal, like a 
monkey, chimp, or fruit bat. After that it moves from one person to another person by the 
same way. Persons who care for a sick person or bury someone who has died from the 
disease often get it. Ebola also spread by touching contaminated needles or surfaces. Ebola 
cannot spread through air, water and food, handling the meat from infected animals, coming 
into contact with the infected person’s blood. A person who has Ebola but has no symptoms 
cannot spread the disease, either [3,4,11,12]. 
5. PATHOGENESIS 
Ebola virus enters in to the body through the mucous membrane, breaking skin and via the 
parenteral route. This pathogen may infect many cells like macrophages, monocytes, 
dendritic cells, endothelial cells, fibroblast, hepatocytes, epithelial cells and adrenal cortex 
cells. Due to outbreak conditions all data of ebola virus pathogenesis obtained by laboratory 
experiments on guinea pigs, mice and other nonhuman primates [13].  
6. ATTACKING SYSTEM OF EBOLA VIRUS IN HUMAN 
When Ebola enters into the human body system, ebola virus protein called VP24 binds with 
the human host protein known as KPNA5. KPNA5’s mainly responsible for the 
communication between cells and transfer signal into and out of nucleus. It works just like a 
messenger. After that KPNA5 transfer all these signals to nucleus of other body parts of the 
cells. These signals regulate various functions in an organism including immune response. 
  
When ebola protein VP24 binds with the messenger protein STAT1, due to this binding it 
doesn’t carry important immune signals; STAT1 is the transporter into the nucleus and 
activates the genes for antiviral responses said by Daisy Leung. Inhibition of PY-STAT1 by 
eVP-24 is due to direct competitions by eVP-24 for NPI-1 subfamily KPNA binding.  
Nucleus receives STAT-1 protein; it sounds like alarm and releases interferon’s for fighting 
with virus, bacteria or whatever other pathogen is attacking the cells. The immune system 
can’t communicate properly because of VP24 is still sitting in STAT1 seat (figure 3) [14].  
 
Figure 3 Schematic representation of Ebola virus killing host system 
7. SYMPTOMS 
Ebola symptoms include headache high fever, Joint aches, muscle aches, weakness, sore 
throat, pain in stomach and lack of appetite. Bleeding occurs inside the body, as well as from 
the eyes, ears, and nose in worst condition of disease.  Some people will vomit or cough 
up blood, have bloody diarrhea, and get a rash [3,4,15]. Transaminitis, leukopenia, 
thrombocytopenia, coagulations abnormalities and renal abnormalities often occur in patient 
with ebola virus by laboratory findings [16].  
8. DIAGNOSIS 
Doctors may prescribe tests like CBC (Complete Blood Count), coagulation studies (a test to 
check for the amount of time a person’s blood needs to clot), viral antigen testing (a test to 
check for the presence of the viral antigen) and a liver function test. 
9. PROGNOSIS 
As per WHO reports, on an average, 80% of the people infected with Ebola virus do die. 
Their death is usually due to a drop in their blood pressure and failure of organs [3,4]. 
10. PREVENTION 
10.1. Control: 
The basic hygiene is of importance and a must be followed in order to prevent the onset of 
the condition. Simple activities like washing your hands well, drinking water from a clean 
source, maintaining general hygiene and cooking your meat well, can all serve as 
precautionary measures [3,4]. 
10.2. Treatment: 
Standard treatment currently consists of supportive therapy, including maintenance of blood 
volume and electrolyte balance, as well as analgesics and standard nursing care [17]. 
Progression of Ebola virus in infected mice is inhibited by some drugs like clomiphene and 
toremiphene. Amiodarone is used in the treatment of heart arrhythmias, is an ion channel 
blocker, which blocks the ebola virus entry into cells in vitro studied shows in 2014 [18].  
Other promising treatments rely on antisense technology. Both small interfering 
RNAs (siRNAs) and phosphorodiamidate morpholino oligomers (PMOs) targeting the Zaire 
Ebola virus (ZEBOV) RNA polymerase L protein could prevent disease in nonhuman 
primates [19,20]. TKM-Ebola is a small-interfering RNA compound, currently tested in a 
phase I clinical trial in people [21,22]. 
  
10.3. Vaccination: 
There aren’t any vaccinations available as of now but According to BBC News on dated 30 
August 2014, ZMapp is a Ebola vaccine shows 100 % success rate, which has been tested on 
18 laboratory monkeys, is due to be put through human trials [23, 24]. 
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